Translational Molecular Oncology

Our research unit is formed by a multidisciplinary team composed of biologists, medical oncologists and pathologists with the common objective of understanding the molecular alterations involved in cancer to help in patients´ diagnosis and prognosis.

We have currently several projects on going aimed to find new biomarkers and molecular targets that can be used towards a precision medicine, opening new avenues in the therapeutic options, using tissue and liquid biopsies. We believe that our work is predestined to have a clear clinical application that could change cancer diagnosis and would help oncologists for personalized treatments.

Team

• Dra Mónica Martínez-Fernández (IP)
• Dr Martín Lázaro (Medical Oncology, CHUVI)
• Dra Noemi de Dios (Medical Oncology, CHUVI)
• Dra Laura Juaneda (Anatomical Pathology, CHUVI)
• Dr Máximo Fraga (Anatomical Pathology, CHUS)
• Sonia Zumalave (PhD student, Xunta grant holder, Genomes and Disease lab, CIMUS)
• Jenifer Brea (PhD student, AECC grant holder, Genomes and Disease lab, CIMUS)
• Ana Oitabén (PhD student, CiMUS grant holder, Genomes and Disease lab, CIMUS)
  
  

Publications

• Martinez VG, …, Martínez-Fernández M and Paramio JM. Epigenetics of Bladder

  Cancer: Where Biomarkers and Therapeutic Targets Meet. Front. Genet. 10:1125 (2019).

• Segovia, San José-Enériz , Munera-Maravilla*, Martínez-Fernández M et al

  Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. Nature Medicine, 25: 1073–1081 (2019).

• Dueñas, …, Mónica Martínez-Fernández.

  Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status. Scientific Reports, 9: 10362 (2019).
  
  

Projects (PI: Mónica Martínez-Fernández)

1. Proyecto de Investigación en Salud del ISCIII, AES2019, “Ampliando el horizonte para los biomarcadores predictores de respuesta a inmmunoterapia”, (2020-2022).
2. AECC Investigator "Estudio del impacto funcional de la transducción de secuencias reguladoras mediada por retrotransposones altamente mutagénicos” (2018-2022).
3. OCTOPUS project: Oncoloxía Customizada para Tratar Os PUlmónS (https://proxectooctopus.org/) funded by the Vigo Against Cancer Association, (2020-).
4. Ideas Semilla AECC: “Estudio de nuevos mecanismos moleculares en la respuesta a inmmunoterapia”, (2020-2022).